Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Myeloproliferative Neoplasm Clinical Trial

Official title:
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Status Not yet recruiting

Clinical Trial Summary

The goal of Part 1 of this clinical research study is to find the highest tolerable dose of ASTX029 that can be given in combination with ASTX727 to participants who have RAS-mutant MDS or MDS/MPN. The goal of Part 2 of this clinical research study is to learn if the dose of ASTX029 found in Part 1 can help to control the disease when used in combination with ASTX727.

Clinical Trial Description

Primary Objectives: - Phase 1 dose escalation: to determine safety, tolerability and MTD of ASTX029 in RAS mutant MDS, CMML and other MDS/MPN - Phase 2 dose expansion: to determine the safety, tolerability and overall response rate (ORR) of ASTX727 in combination with ASTX029 in RAS mutant MDS, CMML and other MDS/MPN - Incidence of AEs, MTD and changes in clinical laboratory values. - Measures of efficacy: overall response rate (ORR) defined as sum of CR + complete cytogenetic remission + partial remission + marrow response + clinical benefit for MDS/MPN and defined as CR + mCR + PR + HI in MDS Secondary Objectives: - To determine other efficacy outcomes such as duration of response, leukemia-free survival (LFS), progression-free survival (PFS) and overall survival (OS). - To evaluate differences in response and efficacy outcomes by MDS/MPN IWG response criteria based on disease subtypes and genomic features. - Correlative studies - To evaluate changes in clonal composition and VAF of identified mutations with therapy. - To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ASTX029 and the combination of ASTX727 with ASTX029 in patients with RAS mutant MDS, CMML and other MDS/MPN ;

Study Design

Related Conditions & MeSH terms

Myelodysplastic Syndromes
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Myeloproliferative Neoplasm
Neoplasms
Preleukemia
Syndrome

Clinical Trial Details

NCT number	NCT06284460
Study type	Interventional
Source	M.D. Anderson Cancer Center
Contact	Guillermo Montalban Bravo, MD
Phone	(713) 794-3604
Email	gmontalban1@mdanderson.org
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	July 31, 2024
Completion date	December 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04022785` - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome	Phase 1
Not yet recruiting	`NCT05440838` - Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
Completed	`NCT03941769` - 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II	Phase 1/Phase 2
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Recruiting	`NCT03589729` - Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers	Phase 2
Completed	`NCT04605211` - A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors	N/A
Active, not recruiting	`NCT03588078` - Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine	Phase 1/Phase 2
Recruiting	`NCT05521204` - Olverembatinib for FGFR1-rearranged Neoplasms	Phase 2
Enrolling by invitation	`NCT04994158` - MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis
Completed	`NCT04192916` - Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Not yet recruiting	`NCT03177928` - Cardiac Changes in Myeloproliferative Neoplasms	N/A
Recruiting	`NCT05419648` - Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)
Recruiting	`NCT04955938` - A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms	Phase 1
Recruiting	`NCT04942080` - Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)	N/A
Completed	`NCT04146038` - Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease	Phase 2
Not yet recruiting	`NCT06468033` - P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk	Phase 3
Completed	`NCT02862366` - Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1-
Not yet recruiting	`NCT06022341` - MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies	N/A
Recruiting	`NCT03630991` - Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy	Phase 1